Past anticompetitive conduct of pharmaceutical companies can signal potential problems with a proposed merger, experts acknowledged, suggesting that the US Federal Trade Commission and Department of Justice consider such behavior a “plus factor” in their analysis of certain mergers.
During the second day of a two-day virtual workshop on pharmaceutical mergers, panelists discussed how a company’s prior “bad acts”...







